246 related articles for article (PubMed ID: 37872011)
1. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
Lasrado N; Collier AY; Hachmann NP; Miller J; Rowe M; Schonberg ED; Rodrigues SL; LaPiana A; Patio RC; Anand T; Fisher J; Mazurek CR; Guan R; Wagh K; Theiler J; Korber BT; Barouch DH
Vaccine; 2023 Nov; 41(47):6904-6909. PubMed ID: 37872011
[TBL] [Abstract][Full Text] [Related]
2. Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1.
Lasrado N; Rössler A; Rowe M; Collier AY; Barouch DH
Vaccine; 2024 Apr; 42(9):2117-2121. PubMed ID: 38458874
[TBL] [Abstract][Full Text] [Related]
3. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
Hu Y; Zou J; Kurhade C; Deng X; Chang HC; Kim DK; Shi PY; Ren P; Xie X
Emerg Microbes Infect; 2023 Dec; 12(2):2271089. PubMed ID: 37824708
[TBL] [Abstract][Full Text] [Related]
4. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
[TBL] [Abstract][Full Text] [Related]
5. Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination.
Ju B; Fan Q; Liu C; Shen S; Wang M; Guo H; Zhou B; Ge X; Zhang Z
Cell Rep; 2023 Jun; 42(6):112532. PubMed ID: 37219999
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
[TBL] [Abstract][Full Text] [Related]
8. Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant.
Khan K; Lustig G; Römer C; Reedoy K; Jule Z; Karim F; Ganga Y; Bernstein M; Baig Z; Jackson L; Mahlangu B; Mnguni A; Nzimande A; Stock N; Kekana D; Ntozini B; van Deventer C; Marshall T; Manickchund N; Gosnell BI; Lessells RJ; Karim QA; Abdool Karim SS; Moosa MS; de Oliveira T; von Gottberg A; Wolter N; Neher RA; Sigal A
Nat Commun; 2023 Dec; 14(1):8078. PubMed ID: 38057313
[TBL] [Abstract][Full Text] [Related]
9. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.
Muik A; Lui BG; Quandt J; Diao H; Fu Y; Bacher M; Gordon J; Toker A; Grosser J; Ozhelvaci O; Grikscheit K; Hoehl S; Kohmer N; Lustig Y; Regev-Yochay G; Ciesek S; Beguir K; Poran A; Vogler I; Türeci Ö; Sahin U
Cell Rep; 2023 Aug; 42(8):112888. PubMed ID: 37527039
[TBL] [Abstract][Full Text] [Related]
10. Neutralization sensitivity of SARS-CoV-2 Omicron variants FL.1 and GE.1 by therapeutic antibodies and XBB sera.
Lee J; Naoe Y; Bang U; Nakagama Y; Saito A; Kido Y; Hotta A
Virology; 2024 Jul; 595():110067. PubMed ID: 38653156
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
[TBL] [Abstract][Full Text] [Related]
12. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
Zhao Q; Wang X; Zhang Z; Liu X; Wang P; Cao J; Liang Q; Qu J; Zhou M
J Med Virol; 2023 Jul; 95(7):e28932. PubMed ID: 37403923
[TBL] [Abstract][Full Text] [Related]
13. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
[TBL] [Abstract][Full Text] [Related]
14. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.
Patel N; Trost JF; Guebre-Xabier M; Zhou H; Norton J; Jiang D; Cai Z; Zhu M; Marchese AM; Greene AM; Mallory RM; Kalkeri R; Dubovsky F; Smith G
Sci Rep; 2023 Nov; 13(1):19176. PubMed ID: 37932354
[TBL] [Abstract][Full Text] [Related]
15. Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5- and BA.5-XBB-convalescent subpopulations.
Yang X; Wang Y; Liang Z; Cui T; Chen D; Li G; Xu H; Liu S; Zhong N; Huang W; Wang Z
J Med Virol; 2024 Jan; 96(1):e29417. PubMed ID: 38258345
[TBL] [Abstract][Full Text] [Related]
16. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
[TBL] [Abstract][Full Text] [Related]
17. Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3.
Faraone JN; Qu P; Goodarzi N; Zheng YM; Carlin C; Saif LJ; Oltz EM; Xu K; Jones D; Gumina RJ; Liu SL
Emerg Microbes Infect; 2023 Dec; 12(2):2270069. PubMed ID: 37819267
[TBL] [Abstract][Full Text] [Related]
18. Low neutralization of SARS-CoV-2 Omicron BA.5.2.48, BF.7.14, XBB.1 subvariants by homologous or heterologous booster.
Li J; Mao H; Song W; Chen Y; Feng Y; Li J; Su L; Li X; Shi W; Wu Y; Huang C; Zhang Y; Chen K
J Med Virol; 2023 Dec; 95(12):e29306. PubMed ID: 38084772
[TBL] [Abstract][Full Text] [Related]
19. Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.
Nham E; Kim J; Lee J; Park H; Kim J; Lee S; Choi J; Kim KT; Yoon JG; Hwang SY; Song JY; Cheong HJ; Kim WJ; Park MS; Noh JY
Immune Netw; 2023 Dec; 23(6):e43. PubMed ID: 38188597
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 Variants Omicron BA.4/5 and XBB.1.5 Significantly Escape T Cell Recognition in Solid-organ Transplant Recipients Vaccinated Against the Ancestral Strain.
Halvorson T; Ivison S; Huang Q; Ladua G; Yotis DM; Mannar D; Subramaniam S; Ferreira VH; Kumar D; Belga S; Levings MK;
Transplantation; 2024 Apr; 108(4):e49-e62. PubMed ID: 38012843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
